Equities Analysts Offer Predictions for ELDN FY2025 Earnings

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) – Equities research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Eledon Pharmaceuticals in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the company will post earnings per share of ($1.12) for the year. The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($0.63) per share.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $16.00 target price on shares of Eledon Pharmaceuticals in a report on Wednesday, November 20th.

Eledon Pharmaceuticals Trading Up 1.7 %

NASDAQ ELDN opened at $4.09 on Wednesday. The stock has a 50-day simple moving average of $4.27 and a two-hundred day simple moving average of $3.44. Eledon Pharmaceuticals has a fifty-two week low of $1.52 and a fifty-two week high of $5.54.

Eledon Pharmaceuticals (NASDAQ:ELDN) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02).

Hedge Funds Weigh In On Eledon Pharmaceuticals

Several large investors have recently made changes to their positions in ELDN. Nantahala Capital Management LLC purchased a new position in Eledon Pharmaceuticals in the second quarter valued at $1,584,000. Inspire Investing LLC acquired a new position in Eledon Pharmaceuticals in the 4th quarter worth about $802,000. Renaissance Technologies LLC boosted its position in Eledon Pharmaceuticals by 57.1% during the second quarter. Renaissance Technologies LLC now owns 136,773 shares of the company’s stock worth $361,000 after purchasing an additional 49,704 shares in the last quarter. Armistice Capital LLC grew its holdings in Eledon Pharmaceuticals by 1.7% in the second quarter. Armistice Capital LLC now owns 2,336,000 shares of the company’s stock valued at $6,167,000 after purchasing an additional 39,000 shares during the period. Finally, Geode Capital Management LLC increased its position in shares of Eledon Pharmaceuticals by 9.7% in the third quarter. Geode Capital Management LLC now owns 378,058 shares of the company’s stock valued at $942,000 after buying an additional 33,569 shares in the last quarter. 56.77% of the stock is currently owned by institutional investors and hedge funds.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).